MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE: BCR) today announced that a U.S. District Court jury in Arizona found that certain of W. L. Gore & Associates Inc.’s ePTFE vascular grafts and stent-grafts infringe Bard patent number 6,436,135. The jury upheld the validity of the patent and awarded $185 million in past damages. The jury also found that Gore willfully infringed the patent.
